Edition:
United States

MabVax Therapeutics Holdings Inc (MBVX.OQ)

MBVX.OQ on NASDAQ Stock Exchange Capital Market

1.53USD
4:00pm EDT
Change (% chg)

$0.04 (+2.68%)
Prev Close
$1.49
Open
$1.52
Day's High
$1.68
Day's Low
$1.40
Volume
13,587
Avg. Vol
19,570
52-wk High
$6.87
52-wk Low
$1.28

Select another date:

Tue, Mar 6 2018

BRIEF-MabVax Therapeutics Regains Compliance With NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement

* MABVAX THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ'S $1.00 MINIMUM BID PRICE MAINTENANCE REQUIREMENT Source text for Eikon: Further company coverage:

BRIEF-Mabvax Therapeutics Reports Positive Safety Results From Initial Cohort Of MVT-1075

* MABVAX THERAPEUTICS REPORTS POSITIVE SAFETY RESULTS FROM INITIAL COHORT OF MVT-1075 RADIOIMMUNOTHERAPY PHASE 1 TRIAL FOR THE TREATMENT OF PANCREATIC, COLON AND LUNG CANCERS

BRIEF-MabVax Therapeutics Says Reverse Stock Split Is Scheduled To Be Effective With Opening Of Trading On Feb 16

* MABVAX THERAPEUTICS SCHEDULES PREVIOUSLY ANNOUNCED 1-FOR-3 REVERSE STOCK SPLIT TO REGAIN COMPLIANCE WITH NASDAQ'S $1.00 MINIMUM BID PRICE MAINTENANCE REQUIREMENT

BRIEF-Barry Honig Reports 4.99 Pct Stake In MabVax Therapeutics

* BARRY HONIG REPORTS 4.99 PERCENT STAKE IN MABVAX THERAPEUTICS HOLDINGS INC AS OF FEBRUARY 12, 2018 - SEC FILING‍​

BRIEF-John Stetson Reports 4.99 Pct Stake In Mabvax Therapeutics Holdings

* JOHN STETSON REPORTS 4.99 PERCENT STAKE IN MABVAX THERAPEUTICS HOLDINGS INC AS OF FEBRUARY 12 - SEC FILING Source text: (http://bit.ly/2EoGXsh) Further company coverage:

BRIEF-MabVax Therapeutics Announces Positive Interim Data From Trial of MVT-5873

* MABVAX THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FROM EXPANDED COHORT IN PHASE 1 TRIAL EVALUATING MVT-5873 IN COMBINATION WITH FIRST-LINE CHEMOTHERAPY IN PANCREATIC CANCER

BRIEF-Mabvax Therapeutics Holdings Provides Business Strategy Update

* MABVAX THERAPEUTICS HOLDINGS, INC. PROVIDES BUSINESS STRATEGY UPDATE

BRIEF-MabVax Therapeutics Files For Resale Of 16.6 Mln Shares Of Co's Common Stock

* MABVAX THERAPEUTICS HOLDINGS INC FILES FOR RESALE OF 16.6 MILLION SHARES OF CO'S COMMON STOCK BY CERTAIN OF CO'S STOCKHOLDERS - SEC FILING Source text: (http://bit.ly/2of4wAj) Further company coverage:

BRIEF-MabVax Completes Enrollment In Initial Cohort Of Its Cancer Drug

* MABVAX THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT AND DOSING IN INITIAL COHORT OF MVT-1075 RADIOIMMUNOTHERAPY PHASE 1 TRIAL FOR THE TREATMENT OF PANCREATIC, COLON AND LUNG CANCERS

BRIEF-Mabvax to present three posters at AACR-NCI-EORTC Int'l conference

* Mabvax therapeutics to present three posters at the aacr-nci-eortc international conference on molecular targets and cancer therapeutics Source text for Eikon: Further company coverage:

Select another date: